Isolation in Brazil of Nosocomial Staphylococcus aureus With Reduced Susceptibility to Vancomycin
暂无分享,去创建一个
L. Cui | K. Hiramatsu | E. M. Mamizuka | G. A. Oliveira | C. Levy | A. DELL’AQUILA | Rita L. Masiero | Marcia S. Gomes | A. Dell'aquila
[1] Arjun Srinivasan,et al. Vancomycin Resistance in Staphylococci , 2002, Clinical Microbiology Reviews.
[2] K. Hiramatsu,et al. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. , 2000, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[3] C. Pai,et al. Vancomycin-Intermediate Staphylococcus aureus in Korea , 2000, Journal of Clinical Microbiology.
[4] H. Murakami,et al. Contribution of a Thickened Cell Wall and Its Glutamine Nonamidated Component to the Vancomycin Resistance Expressed by Staphylococcus aureus Mu50 , 2000, Antimicrobial Agents and Chemotherapy.
[5] R. Jayaswal,et al. Characterization of Passage-Selected Vancomycin-Resistant Staphylococcus aureus Strains of Diverse Parental Backgrounds , 2000, Antimicrobial Agents and Chemotherapy.
[6] S. Boyle-Vavra,et al. Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates , 2000, Antimicrobial Agents and Chemotherapy.
[7] F. Tenover. Implications of vancomycin-resistant Staphylococcus aureus. , 1999, The Journal of hospital infection.
[8] R. Gaynes,et al. Glycopeptide-Intermediate Staphylococcus aureus: Evaluation of a Novel Screening Method and Results of a Survey of Selected U.S. Hospitals , 1999, Journal of Clinical Microbiology.
[9] A. MacGowan,et al. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. , 1999, The Journal of antimicrobial chemotherapy.
[10] J. Aeschlimann,et al. Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.
[11] G. Archer,et al. Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin , 1999, Antimicrobial Agents and Chemotherapy.
[12] A. Tomasz,et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.
[13] B. Robinson-Dunn,et al. Emergence of Vancomycin Resistance inStaphylococcus aureus , 1999 .
[14] K. Hiramatsu,et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. , 1998, The Journal of antimicrobial chemotherapy.
[15] R. Dal-Ré,et al. In Vitro Activities of Co-Amoxiclav at Concentrations Achieved in Human Serum against the Resistant Subpopulation of Heteroresistant Staphylococcus aureus: a Controlled Study with Vancomycin , 1998, Antimicrobial Agents and Chemotherapy.
[16] K. Hiramatsu. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. , 1998, The American journal of medicine.
[17] C. Martín,et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital , 1998, The Lancet.
[18] F. Tenover,et al. Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides , 1998, Journal of Clinical Microbiology.
[19] Y. Fukuchi,et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.
[20] Centersfordiseasecontrolandpr. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. , 1997, MMWR. Morbidity and mortality weekly report.
[21] F. Tenover,et al. Detection of vancomycin-resistant enterococci in fecal samples by PCR , 1997, Journal of clinical microbiology.
[22] L. Doğancı,et al. Overdiagnosis of intestinal amoebosis in Turkey , 1997, The Lancet.
[23] F. Tenover,et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.
[24] D H Persing,et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.
[25] A. Tomasz,et al. Geographic spread of epidemic multiresistant Staphylococcus aureus clone in Brazil , 1995, Journal of clinical microbiology.
[26] R. S. Grinbaum,et al. An Overview of Nosocomial Infection Control in Brazil , 1995, Infection Control & Hospital Epidemiology.
[27] Ronald N. Jones,et al. Evaluation of Interhospital Spread of Methicillin-Resistant Staphylococcus aureus in Sao Paulo, Brazil, Using Pulsed-Field Gel Electrophoresis of Chromosomal DNA , 1994, Infection Control & Hospital Epidemiology.
[28] F. Tenover,et al. Characterization of glycopeptide-resistant enterococci from U.S. hospitals , 1993, Antimicrobial Agents and Chemotherapy.
[29] R. Goering,et al. Molecular Epidemiology of Nosocomial Infection: Analysis of Chromosomal Restriction Fragment Patterns by Pulsed-Field Gel Electrophoresis , 1993, Infection Control & Hospital Epidemiology.
[30] T. Rice. Simplified dosing and monitoring of vancomycin for the burn care clinician. , 1992, Burns : journal of the International Society for Burn Injuries.
[31] F. Tenover,et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. , 1999, Emerging infectious diseases.